亚开行-新冠肺炎疫苗生产竞赛：新兴疫苗技术（英）-2023.11-56页_906kb

The Race to Manufacture COVID-19 Vaccines — Emerging Vaccine Technologies

Summary

This document details 16 vaccine manufacturers developing novel technologies for COVID-19 and other pathogens. It examines their platforms, vaccines, and global partnerships to assist developing member countries (DMCs) and low- and middle-income countries (LMICs) in strengthening vaccine manufacturing and procurement.

Contents

• II. Overview of Vaccine Platforms: Types of viral vaccines and their mechanisms.
• III. Vaccine Briefs: Summaries of 16 companies with country and technology details.

Key Manufacturers & Technologies

1. Arcturus Therapeutics (US)

   • Platform: LUNAR+STARR lipid nanoparticles for mRNA/DNA delivery.
   • COVID-19 Booster: ARCT-154 (low-dose, lyophilized).

2. Baiya Phytopharm (Thailand)

   • Platform: Plant-based protein expression for subunit vaccines.
   • COVID-19 Vaccine: Plant-derived RBD, in Phase 3 trials.

3. Beijing Wantai (China)

   • Platform: DNA-based vaccines with recombinant expression.
   • Innovation: Intranasal COVID-19 vaccine (dNS1-RBD).

4. Biological E. Limited (India)

   • Platform: Protein subunit vaccines with adjuvants (Alum, CpG).
   • COVID-19: Corbevax (ancestral RBD booster).

5. CanSino Biologics (China)

   • Platform: Adenovirus vectors, mRNA.
   • Innovation: Inhaled COVID-19 vaccine (Convidecia Air).

Emerging Technologies

Global Partnerships

• LMIC Engagement: Companies collaborate with governments and manufacturers in Southeast Asia, India, and Africa to localize production and improve accessibility.
• Technology Transfer: Includes mRNA platforms (e.g., CSL, Serum Institute of India) for affordable LMIC deployment.

Conclusions

The race to develop COVID-19 vaccines has accelerated emerging technologies like mRNA, DNA, and plant-based vaccines. These innovations promise broader applicability against pandemics and boost equity in global vaccine distribution.